Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BioArctic AB
NeuroDerm Parkinson’s Drug Inches Closer To Market With Phase III Win
Mitsubishi Tanabe Pharma paid $1.1bn to acquire the Israeli biotech in 2017 for a drug that analysts forecast to represent a market opportunity worth up to $1.7bn in peak sales.
Blow For Sweden's BioArctic As AbbVie Exits Parkinson's Pact
Novartis and Roche may be committed to the target, but AbbVie has decided that its efforts in Parkinson's will not include a Phase II trial of its Swedish partner's alpha synuclein drug.
Novartis Will Co-Develop UCB’s Alpha-Syn Inhibitor For Parkinson’s
Deal Snapshot: Seeking to bring a disease-modifying Parkinson’s drug to market, Novartis will team with UCB on developing and commercializing UCB0599, a Phase II oral alpha-synuclein inhibitor.
Eisai Bets On Accelerated Approval For Biogen-Partnered Lecanemab
Following Biogen’s lead with Aduhelm, the first disease-modifying Alzheimer’s therapy approved in the US, Eisai began a rolling BLA submission for lecanemab (BAN2401) ahead of next year’s Phase III results.
- Large Molecule
- Other Names / Subsidiaries
- BioArctic Neuroscience AB
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.